Esperion Therapeutics, Inc.

Listed Company

ESPRCIK 0001434868NasdaqAcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$403.13M

Net Income

$-22.68M

Total Assets

$465.89M

Equity

$-301.96M

Shares Out

256.81M

Op. Cash Flow

$-13.09M

Business

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company developing and commercializing oral, once-daily, non‑statin therapies to address elevated LDL‑C and cardiovascular risk. Its main products are bempedoic acid–based medicines marketed as NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), with related European brand names NILEMDO and NUSTENDI, and a preclinical pipeline of next‑generation ACLY inhibitors. The company operates commercial, research and development, manufacturing oversight, and licensing/collaboration functions. It sells directly in the United States and distributes internationally through regional collaboration, licensing, supply, and royalty arrangements.

Summary from filing dated 2025-03-07

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total Revenues	403	332	116	75	78
Cost of goods sold	129	69	43	—	—
Research and development	48	46	86	119	106
Selling, general and administrative	166	163	143	109	185
Total operating expenses	343	278	272	255	305
Income (loss) from operations	60	54	−156	−180	−227
Interest expense	−85	−59	−59	−57	—
Loss on extinguishment of debt and exchange transaction	0	−55	0	0	—
Other income, net	3	8	5	3	4
Loss before income taxes	−21	−52	−209	—	—
Provision for taxes on income	2	0	0	—	—
Net loss	−23	−52	−209	−234	−269
Net loss per common share - basic (in dollars per share)	−0.11	−0.28	−2.03	−3.52	−9.31
Net loss per common share - diluted (in dollars per share)	−0.11	−0.28	−2.03	−3.52	−9.31
Weighted-average shares outstanding - basic (in shares)	208	187	103	66	29
Weighted-average shares outstanding - diluted (in shares)	208	187	103	66	29
Unrealized gain on investments	0	0	2,000	29,000	−31,000
Total comprehensive loss	−23	−52	−209	−234	−269

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	168	145	82	125	209
Accounts receivable, net	140	80	48	34	23
Inventories, net	105	94	66	35	34
Prepaid clinical development costs	4	586,000	193,000	1	1
Prepaid inventory costs	41	14	—	—	—
Other prepaid and current assets	4	4	5	10	11
Total current assets	463	338	201	247	329
Property and equipment, net	338,000	254,000	0	164,000	664,000
Right of use operating lease assets	3	6	5	1	2
Intangible assets	56,000	56,000	56,000	56,000	—
Total assets	466	344	206	248	382
Accounts payable	65	52	32	23	18
Convertible notes, net of issuance costs	0	55	0	—	—
Accrued clinical development costs	4	5	3	5	7
Accrued variable consideration	88	57	34	22	—
Other accrued liabilities	19	20	25	—	—
Royalty sale liability	88	48	0	—	—
Deferred revenue from collaborations	34	9	25	4	6
Operating lease liabilities	2	3	2	384,000	1
Total current liabilities	301	246	156	92	73
Convertible notes, net of issuance costs	97	97	262	260	258
Royalty sale liability	208	246	0	—	—
Long-term debt	152	141	0	—	—
Operating lease liabilities	653,000	3	3	665,000	524,000
Other long-term liabilities	9	0	—	—	0
Total liabilities	768	733	661	572	579
Commitments and contingencies (Note 5)	—	—	—	—	—
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and December 31, 2024	0	0	0	0	0
Common stock, $0.001 par value; 480,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 247,210,341 shares issued at December 31, 2025 and 197,846,661 shares issued at December 31, 2024	245,000	196,000	118,000	75,000	61,000
Additional paid-in capital	1,376	1,267	1,149	1,071	964
Treasury stock, at cost; 1,994,198 shares at December 31, 2025 and December 31, 2024	−55	−55	−55	−55	—
Accumulated other comprehensive loss	0	0	0	−2,000	−31,000
Accumulated deficit	−1,624	−1,601	−1,549	−1,340	−1,106
Total stockholders' deficit	−302	−389	−455	−324	−197
Total liabilities and stockholders' deficit	466	344	206	248	382

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Non-cash royalty revenue	−55	−26	0	0	—
Paid-in-kind interest on long-term debt	9	0	0	—	—
Non-cash interest expense related to the revenue interest liability	0	22	47	45	34
Non-cash interest expense related to the royalty sale liability	57	25	0	0	—
Stock-based compensation expense	10	12	12	15	24
Depreciation expense	100,000	100,000	200,000	500,000	600,000
Accretion and amortization of premiums and discounts on investments	0	0	−412,000	279,000	12,000
Amortization of debt issuance costs and discounts	3	1	2	2	2
Accounts receivable	−60	−32	−15	−11	−11
Prepaids and other assets	−31	−14	6	1	99,000
Deferred revenue	26	−17	22	−3	5
Inventories	−11	−29	−30	−807,000	−18
Accounts payable	21	12	9	6	—
Other accrued liabilities	31	18	22	4	7
Other long-term liabilities	9	0	0	0	−1
Net cash used in operating activities	−13	−24	−135	−175	−264
Proceeds from sales/maturities of investments	0	0	43	68	0
Purchases of property and equipment	0	−317,000	0	0	0
Net cash (used in) provided by investing activities	0	−317,000	43	8	−50
Proceeds from royalty sale liability	0	305	0	0	—
Payment of royalty sale liability issuance costs	0	−10	0	0	−440,000
Repurchase or principal payment of revenue interest liability	0	−344	0	—	—
Payments on revenue interest liability	0	−6	−16	−8	−3
Proceeds from credit agreement, net of issuance costs	0	145	0	0	—
Proceeds from issuance of convertible notes, net of issuance costs	0	100	0	0	0
Repayment of convertible notes	−55	−210	0	0	—
Proceeds from issuance of common stock, net of issuance costs	73	91	52	0	209
Proceeds from issuance of common stock from ATM Program, net of issuance costs	15	513,000	4	—	—
Proceeds from exercise of warrants	10	15	9	0	—
Payment of issuance costs	−8	0	0	—	—
Other financing activities	244,000	29,000	21,000	−219,000	—
Net cash provided by financing activities	36	86	50	33	268
Net increase (decrease) in cash and cash equivalents	23	63	−43	−134	−46
Issuance costs not yet paid	0	8	635,000	1,000	—
Purchase of property and equipment not yet paid	189,000	0	0	—	0
Non-cash right of use asset	37,000	98,000	115,000	5,000	−7,000
Income taxes paid (refer to Note 17)	612,000	0	0	—	—
Cash paid for interest	16	11	11	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro